>_ QFI Terminal
Terminal › Stocks › RPRX

Royalty Pharma plc (RPRX) Stock

Healthcare · Medical - Pharmaceuticals · US
$58.41 -0.88%
Last updated Sep 20, 2026 14:57 UTC

RPRX Key Statistics

Market Cap$25.89B
P/E (TTM)33.57
P/S (TTM)10.21
P/B (TTM)2.66
Revenue (TTM)$2.54B
EPS (TTM)$1.74
Dividend Yield—
ROE (TTM)12.25%
Net Margin32.15%
Gross Margin89.38%
52W High$64.38
52W Low$34.63
Analyst ViewBuy
Price Target$62.67
Employees100
Volume7,101,192

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

CEO: Pablo Legorreta. Company website

RPRX — Frequently Asked Questions

What is the RPRX stock price today?

Royalty Pharma plc (RPRX) trades at $58.41, down 0.88% on the day, as of Sep 20, 2026 14:57 UTC.

What is Royalty Pharma plc's market cap?

Royalty Pharma plc has a market capitalisation of $25.89B, calculated from the live RPRX share price and shares outstanding.

What is the P/E ratio of RPRX?

RPRX trades at a trailing P/E of 33.57, from earnings per share of $1.74 over the last twelve months.

How much revenue does Royalty Pharma plc make?

Royalty Pharma plc generated revenue of $2.54B over the trailing twelve months, which puts the stock at 10.21 times sales.

What is the 52-week range for RPRX?

RPRX has traded between $34.63 and $64.38 over the past 52 weeks, and the last price is 9.3% below that high.

Is Royalty Pharma plc profitable?

Yes. Royalty Pharma plc keeps 32.15% of revenue as net income over the trailing twelve months.

What is the analyst price target for RPRX?

Wall Street analysts rate RPRX Buy, with an average price target of $62.67, 7.3% above the current price.

What sector is Royalty Pharma plc in?

Royalty Pharma plc is classified under the Healthcare sector and the Medical - Pharmaceuticals industry, and is domiciled in US.

Who is the CEO of Royalty Pharma plc?

Pablo Legorreta is the chief executive of Royalty Pharma plc, which employs 100 people.

Where can I track RPRX in real time?

QFI Terminal shows RPRX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See RPRX live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open RPRX in Terminal See plans

Medical - Pharmaceuticals stocks

CORT Corcept Therapeutics Incorporated BGMSP Bio Green Med Solution, Inc.

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.